Study on the regulation mechanism of Mahuang Xixin Fuzi Decoction on the flora of AR patients based on the overall concept of

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069152

Enrollment

Unknown

Registered

2023-03-08

Start date

2023-03-30

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

Huangxixin Fuzi Decoction Treatment Group:Intervention of Mahuang Xixin Fuzi Decoction

Loratadine treatment group:Intervention of Loratadine

Healthy population group:No intervention

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for AR subjects: (1) It conforms to the diagnostic criteria for moderate to severe AR of yang deficiency type in the Diagnosis and Treatment Guidelines for Allergic Rhinitis of the Chinese Association of Allergy and the Diagnosis and Treatment Guidelines for Common Diseases of Otolaryngology of Traditional Chinese Medicine; ?? (2) Age range: 18 years old = 40 years old (age is calculated according to the difference between screening survey date and birth date); (3) Good compliance; (4) No other research projects in the last month (5) Sign the informed consent form. Inclusion criteria for healthy people: (1) 18 = age = 40 (the age is calculated according to the difference between the screening survey date and the date of birth); (2) No allergic history, allergic disease, respiratory disease, metabolic disease; (3) The physical examination result in the past year was healthy.

Exclusion criteria

Exclusion criteria: Exclusion criteria for AR subjects: (1) Antibiotics have been used for more than 3 days in the past 3 months; In the past 3 months, he has taken anti allergic drugs, hormone drugs, decongestants, etc. orally or locally in the nasal cavity; Use of gastrointestinal motility drugs, microecological regulators and other foods and drugs that affect the intestinal flora in the past 3 months; (2) Women in planned pregnancy, pregnancy or breast-feeding period; (3) Have a history of alcohol abuse, drug abuse or drug abuse; (4) Have intestinal surgery (except for appendicitis and hernia surgery) or any nasal surgery in the past two years; (5) Patients with sinusitis, chronic rhinitis, nasal polyps, vasomotor rhinitis or obvious deviation of nasal septum; (6) People with folliculitis, eczema, chicken pox and other skin diseases; (7) Serious primary diseases or serious organic diseases such as heart, brain, liver, kidney, digestive system, respiratory system, blood system, nervous system, etc; (8) Study the patients with drug contraindication, allergic constitution or other drugs with the same effect. Exclusion criteria for healthy population: (1) The researcher is difficult to cooperate with; (2) Those who used other body conditioning drugs during the test.

Design outcomes

Primary

Measure	Time frame
Total Nasal Symptom Score,TNSS;IgE;histamine;	—

Secondary

Measure	Time frame
Total Non Nasal Symptom Score;rhinoconjunctivitis quality of life question naire;the MOS item short fromhealth survey;Pittsburgh sleep quality index;hospital anxiety and depression scale;TCM Symptom Score Scale;	—

Countries

China

Contacts

Public ContactWenting Ji

Chengdu University of Traditional Chinese Medicine

1422407135@qq.com19182089060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026